Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.

Audrey BenyamineXavier HeimNoémie ResseguierDaniel BertinCarine GomezMikaël EbboJean-Robert HarléGilles KaplanskiPascal Rossi Nathalie BardinBrigitte Granel

Published in: Rheumatology international (2018)

Our study confirms that KL-6 is an accurate biomarker for the diagnosis of SSc-ILD in a French cohort of patients. High KL-6 levels should prompt physicians to assess ILD with pulmonary imaging and pulmonary functions tests. Prospective clinical studies are still required to determine whether levels of KL-6 might predict progression of ILD as well as its usefulness in the timing of therapeutic intervention.

Keyphrases

interstitial lung disease
systemic sclerosis
rheumatoid arthritis
pulmonary hypertension
end stage renal disease
idiopathic pulmonary fibrosis
high resolution
primary care
newly diagnosed
ejection fraction
randomized controlled trial
chronic kidney disease
prognostic factors
mass spectrometry